Provided by Tiger Trade Technology Pte. Ltd.

iShares Health Innovation Active ETF

33.77
0.0000
Volume:144
Turnover:4.86K
Market Cap:13.51M
PE:- -
High:33.77
Open:33.77
Low:33.77
Close:33.77
52wk High:34.98
52wk Low:27.25
Shares:400.00K
Float Shares:400.00K
Volume Ratio:0.20
T/O Rate:0.04%
Dividend:0.08
Dividend Rate:0.24%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Judge Rejects Pfizer, BioNTech, and Moderna Bid to Dismiss Monsanto mRNA Patent Lawsuit

Stock News
·
Sep 29

CARSGEN-B (02171) Completes First Patient Infusion in China Phase I Registration Trial of CT1190B

Stock News
·
Sep 29

Perrigo Co. PLC Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
Sep 29

Estee Lauder Cos. Cl a Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 29

Teva announces FDA approval of Degevma as a biosimilar to Xgeva

TIPRANKS
·
Sep 29

Lawyers in Alabama's TikTok Settlement Set to Earn $14 Million

Reuters
·
Sep 29

Teva Pharmaceutical's Duvakitug Could be Validated by Merck's Tulisokibart Results, Oppenheimer Says

MT Newswires Live
·
Sep 28

Mirum's Liver Infection Drug Lowers Virus Levels in Late-Stage Study

Reuters
·
Sep 28

US Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 28

Johnson & Johnson (JNJ) Gets a Buy from Scotiabank

TIPRANKS
·
Sep 28

Changchun High-Tech's GenSci136 Injection Receives Approval for Domestic Clinical Trial Application

Stock News
·
Sep 28

Xilio Therapeutics Names Yariv Houvras Chief Medical Officer

Reuters
·
Sep 28

U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

GlobeNewswire
·
Sep 28

Merck in License Pact Worth up to $2.13 Billion with SciBrunch Therapeutics

Dow Jones
·
Sep 28

Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine

GlobeNewswire
·
Sep 28

Merck enters global license agreement with SciBrunch Therapeutics for SPR2015

TIPRANKS
·
Sep 28

Merck Enters into Exclusive Global License Agreement with Scibrunch Therapeutics for Spr2015, an Investigational Oral Kras G12d (On) Inhibitor

Reuters
·
Sep 28

Merck & Co - to Record $400 Mln Pre-Tax Charge, $0.13 Per Share, in Q3 2026

THOMSON REUTERS
·
Sep 28

Merck & Co - Deal Includes $400 Mln Upfront, Total Potential Value $2.13 Bln; Deal Closed

THOMSON REUTERS
·
Sep 28

Merck & Co Inc: Under Agreement, Scibrunch Granted Co Exclusive Rights to Develop, Manufacture & Commercialize Spr2015 Worldwide

THOMSON REUTERS
·
Sep 28